Last reviewed · How we verify
S-1 & Oxaliplatin
S-1 is a combination of three components that inhibit thymidylate synthase and fluorodeoxyuridine monophosphate formation, while oxaliplatin is a platinum-based agent that forms DNA crosslinks, together providing synergistic cytotoxic effects against cancer cells.
S-1 is a combination of three components that inhibit thymidylate synthase and fluorodeoxyuridine monophosphate formation, while oxaliplatin is a platinum-based agent that forms DNA crosslinks, together providing synergistic cytotoxic effects against cancer cells. Used for Gastric cancer (advanced or metastatic), Colorectal cancer (advanced or metastatic).
At a glance
| Generic name | S-1 & Oxaliplatin |
|---|---|
| Also known as | S-1 and Oxaliplatin |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Fluoropyrimidine + platinum-based chemotherapy combination |
| Target | Thymidylate synthase (S-1); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
S-1 (tegafur, gimeracil, oteracil potassium) is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase to disrupt DNA synthesis. Oxaliplatin is a third-generation platinum compound that binds DNA and forms interstrand and intrastrand crosslinks, leading to apoptosis. The combination leverages complementary mechanisms of action for enhanced antitumor activity.
Approved indications
- Gastric cancer (advanced or metastatic)
- Colorectal cancer (advanced or metastatic)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Hand-foot syndrome
Key clinical trials
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial (PHASE2)
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (PHASE2)
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1 & Oxaliplatin CI brief — competitive landscape report
- S-1 & Oxaliplatin updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI